1. Home
  2. ICD-10-PCS MS-DRG V41.0
  3. Procedure Codes in MS-DRG 837 - CHEMOTHERAPY WITH ACUTE LEUKEMIA AS SECONDARY DIAGNOSIS OR WITH HIGH DOSE CHEMOTHERAPY AGENT WITH MCC

Procedure Codes in MS-DRG 837 - CHEMOTHERAPY WITH ACUTE LEUKEMIA AS SECONDARY DIAGNOSIS OR WITH HIGH DOSE CHEMOTHERAPY AGENT WITH MCC

The Medicare Severity Diagnosis-Related Group or MS-DRG is a patient classification scheme which provides a means of relating the type of patients a hospital treats. The DRGs divides all possible principal diagnoses into mutually exclusive principal diagnosis areas referred to as Major Diagnostic Categories (MDC). This is the group for Procedure Codes in MS-DRG 837 - CHEMOTHERAPY WITH ACUTE LEUKEMIA AS SECONDARY DIAGNOSIS OR WITH HIGH DOSE CHEMOTHERAPY AGENT WITH Major Complication or Comorbidity diseases in version MS-DRG V41.0 applicable from 10/01/2023 through 09/30/2024.

MS-DRG MS-DRG Title MCD Relative Weight Geometric LOS Arithmetic LOS
837 CHEMOTHERAPY WITH ACUTE LEUKEMIA AS SECONDARY DIAGNOSIS OR WITH HIGH DOSE CHEMOTHERAPY AGENT WITH MCC 17 4.7566 Relative Weight
The relative weight of a diagnostic related group determines the reimbursement rate based on the severity of a patient's illness and the associated cost of care during hospitalization.		 4.84 Geometric Length of Stay
The geometric mean length of stay (GMLOS) is used by Medicare to calculate the reimbursement for patients whose medical treatment takes a much longer or shorter time than average.		 10.90 Arithmetic Length of Stay
The average length of stay (ALOS) reflects the average number of days a patient spends in a hospital for each admission.

ICD-10-PCS Codes in Diagnostic Related Group


  • 3E03
    • 3E03002 Introduction of High-dose Interleukin-2 into Peripheral Vein, Open Approach
    • 3E03302 Introduction of High-dose Interleukin-2 into Peripheral Vein, Percutaneous Approach
  • 3E04
    • 3E04002 Introduction of High-dose Interleukin-2 into Central Vein, Open Approach
    • 3E04302 Introduction of High-dose Interleukin-2 into Central Vein, Percutaneous Approach
  • 3E05
    • 3E05002 Introduction of High-dose Interleukin-2 into Peripheral Artery, Open Approach
    • 3E05302 Introduction of High-dose Interleukin-2 into Peripheral Artery, Percutaneous Approach
  • 3E06
    • 3E06002 Introduction of High-dose Interleukin-2 into Central Artery, Open Approach
    • 3E06302 Introduction of High-dose Interleukin-2 into Central Artery, Percutaneous Approach
  • 3E0R
    • 3E0R302 Introduction of High-dose Interleukin-2 into Spinal Canal, Percutaneous Approach
  • 3E0S
    • 3E0S302 Introduction of High-dose Interleukin-2 into Epidural Space, Percutaneous Approach